山東新華製藥股份(00719.HK)與共同藥業設立合資公司 將投建年產300噸醋酸阿奈可他和200噸17α-羥基黃體酮項目
格隆匯 4 月 13日丨山東新華製藥股份(00719.HK)發佈公吿,為延伸激素系列產品產業鏈,增強市場競爭優勢,結合公司實際及發展規劃,公司與共同藥業(300966.SZ)於2021年4月13日在淄博簽署出資人協議,協議規定雙方共同出資設立山東同新藥業有限公司(暫定名,“同新藥業”或“合資公司”),並投資建設年產300噸醋酸阿奈可他和200噸17α-羥基黃體酮項目。同新藥業註冊資金12,000萬元,其中新華製藥以現金出資人民幣7,200萬元,持股比例60%;共同藥業以現金出資人民幣4,800萬元,持股比例40%。
公吿表示,與共同藥業共同出資設立合資公司,有利於合作雙方加強戰略協同性,形成利益共同體;合資公司設立後,將投資建設年產300噸醋酸阿奈可他和200噸17α-羥基黃體酮項目。投建項目可以延伸新華製藥激素產品產業鏈,進軍國際高端市場,提高盈利能力。項目短期看可以提高激素系列產品的生產、質量穩定性,提升競爭優勢;長期看對公司提高激素系列的抗風險能力、形成規模優勢具有正向促進作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.